{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:37:10Z","timestamp":1794433030315,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AG024904"],"award-info":[{"award-number":["U19AG024904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one \u03b2-amyloid (A\u03b2) radiotracer in positron emission tomography (PET). Variability related to these factors contributes to disagreement and lack of replicability in research and clinical trials. To address these problems and promote A\u03b2 PET harmonization, we used [\n                      <jats:sup>18<\/jats:sup>\n                      F]florbetaben (FBB) and [\n                      <jats:sup>18<\/jats:sup>\n                      F]florbetapir (FBP) data from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) to derive (1) standardized Centiloid (CL) transformations and (2) internally consistent positivity thresholds based on separate young control samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed A\u03b2 PET data using a native-space, automated image processing pipeline that is used for PET quantification in many large, multisite AD studies and trials and made available to the research community. With this pipeline, we derived SUVR-to-CL transformations using the Global Alzheimer\u2019s Association Interactive Network data; we used reference regions for cross-sectional (whole cerebellum) and longitudinal (subcortical white matter, brain stem, whole cerebellum) analyses. Finally, we developed a FBB positivity threshold using an independent young control sample (\n                      <jats:italic>N<\/jats:italic>\n                      =62) with methods parallel to our existing FBP positivity threshold and validated the FBB threshold using a data-driven approach in ADNI participants (\n                      <jats:italic>N<\/jats:italic>\n                      =295).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The FBB threshold based on the young sample (1.08; 18 CL) was consistent with that of the data-driven approach (1.10; 21 CL), and the existing FBP threshold converted to CL with the derived transformation (1.11; 20 CL). The following equations can be used to convert whole cerebellum- (cross-sectional) and composite- (longitudinal) normalized FBB and FBP data quantified with the native-space pipeline to CL units:<\/jats:p>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FBB: CL\n                      <jats:sub>whole cerebellum<\/jats:sub>\n                      \u2009=\u2009157.15\u2009\u00d7\u2009SUVR\n                      <jats:sub>FBB<\/jats:sub>\n                      \u2009\u2212\u2009151.87; threshold=1.08, 18 CL\n                    <\/jats:p>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FBP: CL\n                      <jats:sub>whole cerebellum<\/jats:sub>\n                      \u2009=\u2009188.22\u2009\u00d7\u2009SUVR\n                      <jats:sub>FBP<\/jats:sub>\n                      \u2009\u2212\u2009189.16; threshold=1.11, 20 CL\n                    <\/jats:p>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FBB: CL\n                      <jats:sub>composite<\/jats:sub>\n                      \u2009=\u2009244.20\u2009\u00d7\u2009SUVR\n                      <jats:sub>FBB<\/jats:sub>\n                      \u2009\u2212\u2009170.80\n                    <\/jats:p>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FBP: CL\n                      <jats:sub>composite<\/jats:sub>\n                      \u2009=\u2009300.66\u2009\u00d7\u2009SUVR\n                      <jats:sub>FBP<\/jats:sub>\n                      \u2009\u2212\u2009208.84\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FBB and FBP positivity thresholds derived from independent young control samples and quantified using an automated, native-space approach result in similar CL values. These findings are applicable to thousands of available and anticipated outcomes analyzed using this pipeline and shared with the scientific community. This work demonstrates the feasibility of harmonized PET acquisition and analysis in multisite PET studies and internal consistency of positivity thresholds in standardized units.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00836-1","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T11:04:05Z","timestamp":1620644645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":229,"title":["Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach"],"prefix":"10.1186","volume":"13","author":[{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-0180","authenticated-orcid":false,"given":"Sarah K.","family":"Royse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davneet S.","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lopresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"DeSanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"issue":"3","key":"836_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319. https:\/\/doi.org\/10.1002\/ana.20009.","journal-title":"Ann Neurol."},{"issue":"10","key":"836_CR2","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00259-009-1129-6","volume":"36","author":"N Tolboom","year":"2009","unstructured":"Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2009;36(10):1629\u201338. https:\/\/doi.org\/10.1007\/s00259-009-1129-6.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"836_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54(1):70\u20137. https:\/\/doi.org\/10.2967\/jnumed.112.109009.","journal-title":"J Nucl Med."},{"issue":"9","key":"836_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jalz.2014.09.004","volume":"11","author":"ME Schmidt","year":"2015","unstructured":"Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050\u201368. https:\/\/doi.org\/10.1016\/j.jalz.2014.09.004.","journal-title":"Alzheimers Dement."},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.e1. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"836_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jalz.2012.10.006","volume":"9","author":"MC Carrillo","year":"2013","unstructured":"Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O\u2019Meara T, et al. Research and standardization in Alzheimer\u2019s trials: reaching international consensus. Alzheimers Dement. 2013;9(2):160\u20138. https:\/\/doi.org\/10.1016\/j.jalz.2012.10.006.","journal-title":"Alzheimers Dement."},{"key":"836_CR7","unstructured":"Longitudinal Early-onset Alzheimer\u2019s Disease Study Protocol (LEADS). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03507257. Accessed 12 Feb 2021."},{"key":"836_CR8","unstructured":"Standardized Centralized Alzheimer\u2019s & Related Dementias Neuroimaging. https:\/\/scan.naccdata.org\/. Accessed 12 Feb 2021."},{"key":"836_CR9","unstructured":"Data Usage Statistics. http:\/\/adni.loni.usc.edu\/data-samples\/adni-data-usage-stats\/. Accessed 9 Nov 2020."},{"issue":"12","key":"836_CR10","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dor\u00e9 V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3749-6.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"836_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14(12):1565\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1353.","journal-title":"Alzheimers Dement."},{"issue":"4","key":"836_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56(4):567\u201374. https:\/\/doi.org\/10.2967\/jnumed.114.148981.","journal-title":"J Nucl Med."},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neuroimage.2014.11.055","volume":"108","author":"M Brendel","year":"2015","unstructured":"Brendel M, H\u00f6genauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450\u20139. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.11.055.","journal-title":"Neuroimage."},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"Pt A:113","DOI":"10.1016\/j.neuroimage.2016.08.056","volume":"144","author":"CG Schwarz","year":"2017","unstructured":"Schwarz CG, Senjem ML, Gunter JL, Tosakulwong N, Weigand SD, Kemp BJ, et al. Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage. 2017;144:Pt A:113\u201327. https:\/\/doi.org\/10.1016\/j.neuroimage.2016.08.056.","journal-title":"Neuroimage"},{"issue":"4","key":"836_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-\u03b2 PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56(4):560\u20136. https:\/\/doi.org\/10.2967\/jnumed.114.149732.","journal-title":"J Nucl Med."},{"issue":"8","key":"836_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimers Dement."},{"issue":"5","key":"836_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(11)70077-1.","journal-title":"Lancet Neurol."},{"issue":"6","key":"836_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","volume":"15","author":"V Dor\u00e9","year":"2019","unstructured":"Dor\u00e9 V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, et al. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL\u00ae approaches: validation against histopathology. Alzheimers Dement. 2019;15(6):807\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2019.02.005.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"836_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer\u2019s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378\u201384. https:\/\/doi.org\/10.2967\/jnumed.111.090340.","journal-title":"J Nucl Med."},{"issue":"1","key":"836_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40336-014-0098-3","volume":"3","author":"AM Catafau","year":"2015","unstructured":"Catafau AM, Bullich S. Amyloid PET imaging: applications beyond Alzheimer\u2019s disease. Clin Transl Imaging. 2015;3(1):39\u201355. https:\/\/doi.org\/10.1007\/s40336-014-0098-3.","journal-title":"Clin Transl Imaging."},{"key":"836_CR21","unstructured":"LONI Image Data Archive (IDA). https:\/\/ida.loni.usc.edu\/login.jsp. Accessed 9 Nov 2020."},{"issue":"2","key":"836_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774\u201381. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.01.021.","journal-title":"Neuroimage."},{"issue":"6","key":"836_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.115.161927","volume":"57","author":"J Seibyl","year":"2016","unstructured":"Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J Nucl Med. 2016;57(6):900\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.161927.","journal-title":"J Nucl Med."},{"issue":"6","key":"836_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","volume":"39","author":"VL Villemagne","year":"2012","unstructured":"Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O\u2019Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for A\u03b2 imaging in ageing and Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983\u20139. https:\/\/doi.org\/10.1007\/s00259-012-2088-x.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"supplement 1","key":"836_CR25","first-page":"482","volume":"59","author":"C Rowe","year":"2018","unstructured":"Rowe C, Amadoru S, Dore V, McLean C, Hinton F, Shepherd C, et al. Correlation of amyloid PET in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. J Nucl Med. 2018;59(supplement 1):482.","journal-title":"J Nucl Med"},{"issue":"1","key":"836_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27. https:\/\/doi.org\/10.1186\/s13195-019-0478-z.","journal-title":"Alzheimers Res Ther."},{"issue":"2","key":"836_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.001.","journal-title":"Alzheimers Dement."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00836-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00836-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00836-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T11:08:56Z","timestamp":1620644936000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00836-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00836-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"21 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bullich is an employee of Life Molecular Imaging GmbH (formerly Piramal Imaging GmbH). Dr. DeSanti is an employee of Eisai Inc. and a former employee of Life Molecular Imaging (formerly Piramal Pharma Inc). Dr. Jagust has served as a consultant to Genentech, Novartis, Bioclinica, and Biogen. Dr. Landau has served as a consultant to Cortexyme and NeuroVision.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}